Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example

Haitham A. Badr, Dina M M AlSadek, Motawa E. El-Houseini, Christopher T. Saeui, Mohit P. Mathew, Kevin J Yarema, Hafiz Ahmed

Research output: Contribution to journalReview article

Abstract

Abnormal cell surface display of sialic acids – a family of unusual 9-carbon sugars - is widely recognized as distinguishing feature of many types of cancer. Sialoglycans, however, typically cannot be identified with sufficiently high reproducibility and sensitivity to serve as clinically accepted biomarkers and similarly, almost all efforts to exploit cancer-specific differences in sialylation signatures for therapy remain in early stage development. In this report we provide an overview of important facets of glycosylation that contribute to cancer in general with a focus on breast cancer as an example of malignant disease characterized by aberrant sialylation. We then describe how cancer cells experience nutrient deprivation during oncogenesis and discuss how the resulting metabolic reprogramming, which endows breast cancer cells with the ability to obtain nutrients during scarcity, constitutes an “Achilles' heel” that we believe can be exploited by metabolic glycoengineering (MGE) strategies to develop new diagnostic methods and therapeutic approaches. In particular, we hypothesize that adaptations made by breast cancer cells that allow them to efficiently scavenge sialic acid during times of nutrient deprivation renders them vulnerable to MGE, which refers to the use of exogenously-supplied, non-natural monosaccharide analogues to modulate targeted aspects of glycosylation in living cells and animals. In specific, once non-natural sialosides are incorporated into the cancer “sialome” they can be exploited as epitopes for immunotherapy or as chemical tags for targeted delivery of imaging or therapeutic agents selectively to tumors.

Original languageEnglish (US)
Pages (from-to)158-173
Number of pages16
JournalBiomaterials
Volume116
DOIs
StatePublished - Feb 1 2017

Fingerprint

N-Acetylneuraminic Acid
Metabolism
Cells
Breast Neoplasms
Nutrients
Glycosylation
Acids
Neoplasms
Sialic Acids
Epitopes
Food
Monosaccharides
Biomarkers
Sugars
Tumors
Animals
Carbon
Display devices
Imaging techniques
Immunotherapy

Keywords

  • Biomarkers discovery
  • Cancer metabolism
  • Glycan sialylation
  • Metabolic glycoengineering
  • Nutrient deprivation
  • Nutrient utilization
  • Sialic acid glycoengineering

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example. / Badr, Haitham A.; AlSadek, Dina M M; El-Houseini, Motawa E.; Saeui, Christopher T.; Mathew, Mohit P.; Yarema, Kevin J; Ahmed, Hafiz.

In: Biomaterials, Vol. 116, 01.02.2017, p. 158-173.

Research output: Contribution to journalReview article

Badr, Haitham A. ; AlSadek, Dina M M ; El-Houseini, Motawa E. ; Saeui, Christopher T. ; Mathew, Mohit P. ; Yarema, Kevin J ; Ahmed, Hafiz. / Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example. In: Biomaterials. 2017 ; Vol. 116. pp. 158-173.
@article{fd32dd1761dc4055b2781d52a49091e1,
title = "Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example",
abstract = "Abnormal cell surface display of sialic acids – a family of unusual 9-carbon sugars - is widely recognized as distinguishing feature of many types of cancer. Sialoglycans, however, typically cannot be identified with sufficiently high reproducibility and sensitivity to serve as clinically accepted biomarkers and similarly, almost all efforts to exploit cancer-specific differences in sialylation signatures for therapy remain in early stage development. In this report we provide an overview of important facets of glycosylation that contribute to cancer in general with a focus on breast cancer as an example of malignant disease characterized by aberrant sialylation. We then describe how cancer cells experience nutrient deprivation during oncogenesis and discuss how the resulting metabolic reprogramming, which endows breast cancer cells with the ability to obtain nutrients during scarcity, constitutes an “Achilles' heel” that we believe can be exploited by metabolic glycoengineering (MGE) strategies to develop new diagnostic methods and therapeutic approaches. In particular, we hypothesize that adaptations made by breast cancer cells that allow them to efficiently scavenge sialic acid during times of nutrient deprivation renders them vulnerable to MGE, which refers to the use of exogenously-supplied, non-natural monosaccharide analogues to modulate targeted aspects of glycosylation in living cells and animals. In specific, once non-natural sialosides are incorporated into the cancer “sialome” they can be exploited as epitopes for immunotherapy or as chemical tags for targeted delivery of imaging or therapeutic agents selectively to tumors.",
keywords = "Biomarkers discovery, Cancer metabolism, Glycan sialylation, Metabolic glycoengineering, Nutrient deprivation, Nutrient utilization, Sialic acid glycoengineering",
author = "Badr, {Haitham A.} and AlSadek, {Dina M M} and El-Houseini, {Motawa E.} and Saeui, {Christopher T.} and Mathew, {Mohit P.} and Yarema, {Kevin J} and Hafiz Ahmed",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.biomaterials.2016.11.044",
language = "English (US)",
volume = "116",
pages = "158--173",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example

AU - Badr, Haitham A.

AU - AlSadek, Dina M M

AU - El-Houseini, Motawa E.

AU - Saeui, Christopher T.

AU - Mathew, Mohit P.

AU - Yarema, Kevin J

AU - Ahmed, Hafiz

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Abnormal cell surface display of sialic acids – a family of unusual 9-carbon sugars - is widely recognized as distinguishing feature of many types of cancer. Sialoglycans, however, typically cannot be identified with sufficiently high reproducibility and sensitivity to serve as clinically accepted biomarkers and similarly, almost all efforts to exploit cancer-specific differences in sialylation signatures for therapy remain in early stage development. In this report we provide an overview of important facets of glycosylation that contribute to cancer in general with a focus on breast cancer as an example of malignant disease characterized by aberrant sialylation. We then describe how cancer cells experience nutrient deprivation during oncogenesis and discuss how the resulting metabolic reprogramming, which endows breast cancer cells with the ability to obtain nutrients during scarcity, constitutes an “Achilles' heel” that we believe can be exploited by metabolic glycoengineering (MGE) strategies to develop new diagnostic methods and therapeutic approaches. In particular, we hypothesize that adaptations made by breast cancer cells that allow them to efficiently scavenge sialic acid during times of nutrient deprivation renders them vulnerable to MGE, which refers to the use of exogenously-supplied, non-natural monosaccharide analogues to modulate targeted aspects of glycosylation in living cells and animals. In specific, once non-natural sialosides are incorporated into the cancer “sialome” they can be exploited as epitopes for immunotherapy or as chemical tags for targeted delivery of imaging or therapeutic agents selectively to tumors.

AB - Abnormal cell surface display of sialic acids – a family of unusual 9-carbon sugars - is widely recognized as distinguishing feature of many types of cancer. Sialoglycans, however, typically cannot be identified with sufficiently high reproducibility and sensitivity to serve as clinically accepted biomarkers and similarly, almost all efforts to exploit cancer-specific differences in sialylation signatures for therapy remain in early stage development. In this report we provide an overview of important facets of glycosylation that contribute to cancer in general with a focus on breast cancer as an example of malignant disease characterized by aberrant sialylation. We then describe how cancer cells experience nutrient deprivation during oncogenesis and discuss how the resulting metabolic reprogramming, which endows breast cancer cells with the ability to obtain nutrients during scarcity, constitutes an “Achilles' heel” that we believe can be exploited by metabolic glycoengineering (MGE) strategies to develop new diagnostic methods and therapeutic approaches. In particular, we hypothesize that adaptations made by breast cancer cells that allow them to efficiently scavenge sialic acid during times of nutrient deprivation renders them vulnerable to MGE, which refers to the use of exogenously-supplied, non-natural monosaccharide analogues to modulate targeted aspects of glycosylation in living cells and animals. In specific, once non-natural sialosides are incorporated into the cancer “sialome” they can be exploited as epitopes for immunotherapy or as chemical tags for targeted delivery of imaging or therapeutic agents selectively to tumors.

KW - Biomarkers discovery

KW - Cancer metabolism

KW - Glycan sialylation

KW - Metabolic glycoengineering

KW - Nutrient deprivation

KW - Nutrient utilization

KW - Sialic acid glycoengineering

UR - http://www.scopus.com/inward/record.url?scp=85001105655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85001105655&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2016.11.044

DO - 10.1016/j.biomaterials.2016.11.044

M3 - Review article

C2 - 27926828

AN - SCOPUS:85001105655

VL - 116

SP - 158

EP - 173

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -